Qiagen N.V. (QGEN)

42.95 +0.37 (+0.87%) 收市：04:00PM EDT

Qiagen N.V.

Hulsterweg 82
Venlo 5912 PL
Netherlands
31 77 355 6600
https://www.qiagen.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 5,900

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Thierry Bernard	CEO, MD & Member of Management Board	1.99M	無	1965
Dr. Roland Sackers	CFO, MD & Member of Management Board	1.07M	無	1969
Mr. Antonio Santos	Senior VP & Head of Global Operations	無	無	無
Mr. John Gilardi	Vice President of Corporate Communications & Investor Relations	無	無	無
Ms. Stephany Foster	Senior VP & Head of Human Resources	無	無	1979
Dr. Thomas Schweins	Senior Vice President of Life Science Business Area	無	無	無
Dr. Thomas Theuringer	Senior Director & Head of External Communications	無	無	無
Mr. Jean-Pascal Viola	Senior VP & Head of Molecular Diagnostics Business Area	無	無	無
Dr. Jonathan G. Sheldon Ph.D.	Senior Vice President of Qiagen Digital Insights Business Area	無	無	1972

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

公司管治

截至 2024年5月1日 止，Qiagen N.V. 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：1；董事會：3；股東權利：5；現金賠償：3。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。